SciBase Breaks U.S. Reimbursement Barrier with Highmark Coverage for Nevisense
Event summary
- SciBase's Nevisense secures first U.S. payer coverage from Highmark Blue Cross Blue Shield on October 14, 2026.
- Coverage applies to Highmark's 7 million members and self-funded employer groups electing the policy.
- Highmark cites NCCN and AAD guidelines in supporting the medical necessity of Nevisense for melanoma detection.
- Policy covers CPT code 0658T for evaluating suspicious pigmented lesions under specific clinical criteria.
- SciBase aims to expand commercial activity in regions with available reimbursement.
The big picture
SciBase's Highmark coverage marks a strategic inflection point in its U.S. commercialization strategy, addressing a key barrier to scale in the $4-4.5 million annual skin biopsy market. The decision validates Nevisense's role in melanoma detection and sets a precedent for broader payer adoption. With approximately 6,000 relevant dermatology clinics in the U.S., this milestone could unlock significant growth potential for the company's AI-driven dermatology platform.
What we're watching
- Payer Expansion
- Whether SciBase can secure additional payer agreements beyond Highmark to accelerate U.S. market penetration.
- Commercial Momentum
- The pace at which reimbursement coverage converts existing clinical adoption into broader utilization.
- Regulatory Alignment
- How other payers may reference NCCN and AAD guidelines in evaluating Nevisense for coverage.
